Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Miguel Martín, F. Holmes, B. Ejlertsen, S. Delaloge +496 more
Researcher profile · Semantic Scholar
Miguel Martín, F. Holmes, B. Ejlertsen, S. Delaloge +496 more
Cara N Cacioppo, B. Egleston, D. Fetzer, Colleen Burke Sands +16 more
N. Shore, B. Mellado, Satish Shah, R. Hauke +5 more
L. Pan, S. Baek, P. Edmonds, M. Roach +5 more
R. Ramanathan, G. Thomas, A. Khorana, Satish Shah +5 more
M. Taplin, A. Hussain, Satish Shah, N. Shore +16 more
W. Park, Jian Zhang, F. Dayyani, Jianzhen Shan +14 more
M. Taplin, A. Hussain, Satish Shah, N. Shore +20 more
K. He, David Carbone, M. McKean, R. Balaraman +12 more
I. Winer, M. Barve, Satish Shah, Manish R. Sharma +5 more
Y. Janjigian, Wei-Jing Sun, C. M. R. Rocha Lima, Satish Shah +16 more
R. Ramanathan, V. Gressler, Satish Shah, D. Loury +2 more
F. Meric-Bernstam, Satish Shah, Manish R Sharma, A. Metcalfe +4 more
R. Ramanathan, M. Chadha, V. Gressler, Satish Shah +4 more
H. Myint, Satish Shah, M. Gutierrez, Emese Zsíros +14 more
L. Pan, S. Baek, P. Edmonds, M. Roach +5 more
M. Calero, M. Agulnik, M. Mita, Alain C. Mita +20 more
L. Pan, S. Baek, P. Edmonds, M. Roach +5 more
N. Shore, B. Mellado, Satish Shah, R. Hauke +6 more